Skip to main content

Table 1 Clinicopathological characteristics of the four TNBC subtypes based on the FUSCC classification criteria

From: Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer

  

FUSCC subtypes

 

Characteristics

Number

IM

LAR

MES

BLIS

P

(total = 165)

n = 28

n = 29

n = 55

n = 53

Age, y

     

0.024

 ≤50

68

14 (50.0)

6 (20.7)

20 (36.4)

28 (52.8)

 

 >50

97

14 (50.0)

23 (79.3)

35 (63.6)

25 (47.2)

 

Menopause

     

0.160

 Yes

101

16 (57.1)

23 (79.3)

33 (60.0)

29 (54.7)

 

 No

64

12 (42.9)

6 (20.7)

22 (40.0)

24 (45.3)

 

Tunor size, cm

     

0.409

 ≤2 cm

58

14 (50.0)

12 (41.4)

15 (27.3)

17 (32.1)

 

 >2 cm

104

13 (46.4)

17 (58.6)

39 (70.9)

35 (66.0)

 

 Unknown

3

1 (3.6)

0 (0.0)

1 (1.8)

1 (1.9)

 

Tumor grade

     

0.311

  ≤ II

32

4 (14.3)

9 (31.0)

13 (23.6)

6 (11.3)

 

  > II

104

17 (60.7)

17 (58.6)

33 (60.0)

37 (69.8)

 

 Unknown

29

7 (25.0)

3 (10.3)

9 (16.4)

10 (18.9)

 

Ki67, %

     

0.286

 <14

8

0 (0.0)

0 (0.0)

3 (5.5)

5 (9.4)

 

 ≥14

156

28 (100.0)

29 (100.0)

51 (92.7)

48 (90.6)

 

 Unknown

1

0 (0.0)

0 (0.0)

1 (1.8)

0 (0.0)

 

Positive lymph nodes

     

0.019

 0

86

8 (28.6)

13 (44.8)

28 (50.9)

37 (69.8)

 

 1-3

29

6 (21.4)

5 (17.2)

10 (18.2)

8 (15.1)

 

  > 3

50

14 (50.0)

11 (37.9)

17 (30.9)

8 (15.1)

 

Chemotherapy

     

0.642

 Taxane-based

124

21 (75.0)

22 (75.9)

42 (76.4)

39 (73.6)

 

 Non-taxane-based

27

5 (17.9)

3 (10.3)

11 (20.0)

8 (15.1)

 

 Unknown

14

2 (7.1)

4 (13.8)

2 (3.6)

6 (11.3)

 

Radiotherapy

     

0.038

 Yes

50

16 (57.1)

9 (31.0)

14 (25.5)

11 (20.8)

 

 No

103

11 (39.3)

20 (69.0)

37 (67.3)

35 (66.0)

 

 Unknown

12

1 (3.6)

0 (0.0)

4 (7.3)

6 (11.3)

 

Follow up, month

      

 Median

13.9

14.7

12.4

14.3

12.6

 

 IQR

8.6–21.1

10.0–22.4

8.6–19.0

10.6–21.5

8.0–18.4

 

RFS events

22

5

4

4

9

 
  1. BLIS basal-like and immune suppressed, FUSCC Fudan University Shanghai Cancer Center, IM immunomodulatory, IQR interquartile range, LAR luminal androgen receptor, MES mesenchymal-like, RFS recurrence-free survival